3 studies found for:    21282551 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NYESO-1 Murine TCR-Gene Engineered Lymphocytes
Condition: Metastatic Cancers Other Than Melanoma That Express ESO Antigen
Interventions: Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin
2 Recruiting Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01-restricted TCR-Gene Engineered Lymphocytes and Aldesleukin
Conditions: Metastatic Cancer;   Metastatic Melanoma
Interventions: Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR
3 Recruiting Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin
Condition: Metastatic Cancer That Express the MAGE-A3-DP4 Antigen
Interventions: Biological: Anti-MAGE-A3-DP4 TCR;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin

Indicates status has not been verified in more than two years